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Society for Blood are Marrow Transplantation are to:
- Define commonly accepted medical practice
- Develop standards of medical care for autologous
and allogeneic transplants
- Provide recommendations and guidelines for the
role of transplantation as a therapeutic approach
for reimbursement by third-party payers.
To this end, in 1999 the Society began the devel-
opment of evidence-based reviews of the scientific
and medical literature to document when blood and
marrow transplantation is indicated in the treatment
of selected diseases.
GOALS
The goals of the evidence-based reviews are to:
- Determine which disease will be the subject of each
review, establish the focus for each review and de-
velop a list of questions to be addressed
- Assemble and critically evaluate all the valid, peer-
reviewed evidence regarding the role of cytotoxic
therapy with hematopoietic stem cell transplanta-
tion related to the disease
- Make treatment recommendations based on the
available evidence
- Identify discrepancies in study design or methodol-
ogy among published studies that may impact on
the quality of the evidence
- Identify needed areas of additional research
GUIDELINES
The following guidelines are offered for the role of
stem cell transplantation (SCT) as therapy for acutemyeloid leukemia (AML) in adults, and are based on
consensus reached by an expert panel1 following an
evidence-based review of the literature2:
Transplantation versus Chemotherapy
1. There is no significant advantage of autologous
SCT over chemotherapy. Most of the data reflect
outmoded treatment strategies, however, and stud-
ies usingmodern technologiesmay affect outcomes.
2. There is a survival advantage for allogeneic SCT vs.
chemotherapy for patients under age 55 with high
risk cytogenetics.
3. There is insufficient evidence to routinely recom-
mend allogeneic SCT for patients with intermedi-
ate risk cytogenetics, although this is a reasonable
strategy.
4. There is no survival advantage for allogeneic SCT
in patients under age 55 with low risk cytogenetics.
5. There are insufficient data to make a recommenda-
tion for the use of myeloablative regimens for pa-
tients over age 55.
6. There are insufficient data to make a recommenda-
tion for reduced intensity conditioning (RIC) allo-
geneic SCT vs. chemotherapy.
7. For patients in second complete remission,
allogeneic SCT is recommended if there is an
available donor. Otherwise an autologous SCT is
recommended.
Transplantation Techniques
1. An HLA-matched related donor allogeneic SCT is
recommended over autologous SCT, if a matched1Expert panelmembers and authors of the review are: Denise
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donor allogeneic SCT, there are insufficient data
to make a recommendation over autologous SCT.
Available studies, however, do not reflect modern
techniques in supportive care, stem cell source, or
the use of molecular HLA typing.
2. Autologous peripheral blood stem cell transplant
(PBSCT) is recommended over autologous bone
marrow transplant (BMT) due to improvements
in safety and early mortality. Long-term outcomes
have not been studied prospectively, however, and
the impact of autologous PBSCT on overall sur-
vival is not known.
3. There is no evidence of a survival advantage with
purged BMT and insufficient data tomake a recom-
mendation for purging of PBSCT for autologous
SCT.
4. There are insufficient data to make a recommenda-
tion for tandem vs. single autologous SCT.
5. Allogeneic SCT with a matched related donor is
recommended if available. Amatched unrelated do-
nor allogeneic SCT using reduced intensity condi-
tioning may provide equivalent outcomes.
6. There is no evidence of a survival advantage with
T-cell depleted grafts from allogeneic donors.
7. For high risk disease, allogeneic PBSCT is recom-
mended over BMT. For low risk disease, allogeneic
PBSCT and BMT have equivalent outcomes.8. There are insufficient data to make a recommenda-
tion for PBSCT vs. BMT in matched unrelated
donor SCT.
Therapy Regimens
1. There is no evidence of a survival advantage with
any one high dose therapy regimen in autologous
SCT.
2. There is no significant survival advantage with any
one myeloablative conditioning regimen in alloge-
neic SCT. Studies of late effects may change this
recommendation.
3. Fractionated rather than a single dose total body ir-
radiation (TBI) conditioning regimen is recom-
mended in allogeneic SCT.
4. There are insufficient data to make a recommenda-
tion for RIC for allogeneic SCT. The use of RIC is
dependent on patient characteristics.
*A separate evidence-based review3 is available for
the role of SCT in pediatric AML patients.
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